Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PCYC's Cash to Debt is ranked higher than
82% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. PCYC: No Debt )
PCYC' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: No Debt

Equity to Asset 0.78
PCYC's Equity to Asset is ranked higher than
82% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. PCYC: 0.78 )
PCYC' s 10-Year Equity to Asset Range
Min: -0.49   Max: 0.98
Current: 0.78

-0.49
0.98
Interest Coverage No Debt
PCYC's Interest Coverage is ranked higher than
73% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PCYC: No Debt )
PCYC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 52.50
M-Score: 0.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 16.77
PCYC's Operating margin (%) is ranked higher than
92% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. PCYC: 16.77 )
PCYC' s 10-Year Operating margin (%) Range
Min: -24376.8   Max: 37.64
Current: 16.77

-24376.8
37.64
Net-margin (%) 11.80
PCYC's Net-margin (%) is ranked higher than
89% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. PCYC: 11.80 )
PCYC' s 10-Year Net-margin (%) Range
Min: -23291.71   Max: 25.76
Current: 11.8

-23291.71
25.76
ROE (%) 12.32
PCYC's ROE (%) is ranked higher than
93% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. PCYC: 12.32 )
PCYC' s 10-Year ROE (%) Range
Min: -318.92   Max: 17.64
Current: 12.32

-318.92
17.64
ROA (%) 9.86
PCYC's ROA (%) is ranked higher than
94% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. PCYC: 9.86 )
PCYC' s 10-Year ROA (%) Range
Min: -127.89   Max: 13.57
Current: 9.86

-127.89
13.57
ROC (Joel Greenblatt) (%) 365.90
PCYC's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. PCYC: 365.90 )
PCYC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5354.61   Max: 460.92
Current: 365.9

-5354.61
460.92
Revenue Growth (3Y)(%) 305.60
PCYC's Revenue Growth (3Y)(%) is ranked higher than
100% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. PCYC: 305.60 )
PCYC' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 305.6
Current: 305.6

0
305.6
» PCYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PCYC Guru Trades in Q1 2014

Joel Greenblatt 9,591 sh (New)
Jim Simons 47,700 sh (New)
Mariko Gordon 9,295 sh (+112.41%)
Murray Stahl 6,864 sh (+35.25%)
PRIMECAP Management 2,380,739 sh (unchged)
Steven Cohen 388,523 sh (-58.66%)
» More
Q2 2014

PCYC Guru Trades in Q2 2014

Ken Fisher 5,114 sh (New)
Joel Greenblatt 79,089 sh (+724.62%)
Murray Stahl 8,783 sh (+27.96%)
Jim Simons 60,400 sh (+26.62%)
Steven Cohen 574,900 sh (unchged)
Mariko Gordon 4,000 sh (unchged)
Mariko Gordon Sold Out
PRIMECAP Management 2,313,039 sh (-2.84%)
» More
Q3 2014

PCYC Guru Trades in Q3 2014

Steven Cohen Sold Out
Joel Greenblatt Sold Out
Jim Simons Sold Out
PRIMECAP Management 2,311,039 sh (-0.09%)
Murray Stahl 7,003 sh (-20.27%)
Ken Fisher 3,244 sh (-36.57%)
» More
Q4 2014

PCYC Guru Trades in Q4 2014

Jim Simons 108,000 sh (New)
Joel Greenblatt 2,619 sh (New)
Ken Fisher 3,264 sh (+0.62%)
PRIMECAP Management 2,310,539 sh (-0.02%)
Murray Stahl 6,401 sh (-8.60%)
» More
» Details

Insider Trades

Latest Guru Trades with PCYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 238.20
PCYC's P/E(ttm) is ranked higher than
87% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PCYC: 238.20 )
PCYC' s 10-Year P/E(ttm) Range
Min: 35.9   Max: 496.74
Current: 238.2

35.9
496.74
Forward P/E 63.29
PCYC's Forward P/E is ranked higher than
87% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PCYC: 63.29 )
N/A
PE(NRI) 237.60
PCYC's PE(NRI) is ranked higher than
88% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PCYC: 237.60 )
PCYC' s 10-Year PE(NRI) Range
Min: 35.77   Max: 479
Current: 237.6

35.77
479
P/B 23.50
PCYC's P/B is ranked lower than
53% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. PCYC: 23.50 )
PCYC' s 10-Year P/B Range
Min: 0.24   Max: 35.11
Current: 23.5

0.24
35.11
P/S 27.40
PCYC's P/S is ranked higher than
66% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. PCYC: 27.40 )
PCYC' s 10-Year P/S Range
Min: 10.87   Max: 617
Current: 27.4

10.87
617
PFCF 125.70
PCYC's PFCF is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PCYC: 125.70 )
PCYC' s 10-Year PFCF Range
Min: 8.05   Max: 218.11
Current: 125.7

8.05
218.11
POCF 110.11
PCYC's POCF is ranked higher than
89% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PCYC: 110.11 )
PCYC' s 10-Year POCF Range
Min: 7.89   Max: 172.33
Current: 110.11

7.89
172.33
EV-to-EBIT 152.36
PCYC's EV-to-EBIT is ranked higher than
89% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PCYC: 152.36 )
PCYC' s 10-Year EV-to-EBIT Range
Min: -28.2   Max: 400.3
Current: 152.36

-28.2
400.3
Shiller P/E 674.50
PCYC's Shiller P/E is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PCYC: 674.50 )
PCYC' s 10-Year Shiller P/E Range
Min: 326.84   Max: 5053.67
Current: 674.5

326.84
5053.67
Current Ratio 5.23
PCYC's Current Ratio is ranked higher than
76% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. PCYC: 5.23 )
PCYC' s 10-Year Current Ratio Range
Min: 0.14   Max: 49.32
Current: 5.23

0.14
49.32
Quick Ratio 5.05
PCYC's Quick Ratio is ranked higher than
77% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. PCYC: 5.05 )
PCYC' s 10-Year Quick Ratio Range
Min: 0.14   Max: 49.32
Current: 5.05

0.14
49.32
Days Inventory 42.60
PCYC's Days Inventory is ranked higher than
95% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PCYC: 42.60 )
PCYC' s 10-Year Days Inventory Range
Min: 32.23   Max: 656.97
Current: 42.6

32.23
656.97
Days Sales Outstanding 32.16
PCYC's Days Sales Outstanding is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. PCYC: 32.16 )
PCYC' s 10-Year Days Sales Outstanding Range
Min: 2.39   Max: 54.75
Current: 32.16

2.39
54.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 31.10
PCYC's Price/Net Cash is ranked higher than
67% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. PCYC: 31.10 )
PCYC' s 10-Year Price/Net Cash Range
Min: 0.65   Max: 32.51
Current: 31.1

0.65
32.51
Price/Net Current Asset Value 28.10
PCYC's Price/Net Current Asset Value is ranked higher than
64% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. PCYC: 28.10 )
PCYC' s 10-Year Price/Net Current Asset Value Range
Min: 0.64   Max: 30.01
Current: 28.1

0.64
30.01
Price/Tangible Book 23.70
PCYC's Price/Tangible Book is ranked lower than
51% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. PCYC: 23.70 )
PCYC' s 10-Year Price/Tangible Book Range
Min: 0.61   Max: 28.59
Current: 23.7

0.61
28.59
Price/DCF (Projected) 15.90
PCYC's Price/DCF (Projected) is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PCYC: 15.90 )
PCYC' s 10-Year Price/DCF (Projected) Range
Min: 7.57   Max: 50
Current: 15.9

7.57
50
Price/Median PS Value 0.50
PCYC's Price/Median PS Value is ranked higher than
96% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. PCYC: 0.50 )
PCYC' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 10.68
Current: 0.5

0.25
10.68
Price/Graham Number 15.40
PCYC's Price/Graham Number is ranked higher than
88% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PCYC: 15.40 )
PCYC' s 10-Year Price/Graham Number Range
Min: 7.36   Max: 20.08
Current: 15.4

7.36
20.08
Earnings Yield (Greenblatt) 0.70
PCYC's Earnings Yield (Greenblatt) is ranked higher than
87% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. PCYC: 0.70 )
PCYC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 13078.4
Current: 0.7

0.2
13078.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PY2.Germany,
Pharmacyclics Inc was incorporated in Delaware in 1991 and commenced operations in 1992. It is a biopharmaceutical company designing, developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. On November 13, 2013, the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib, PCI-32765) as a monotherapy for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and concurrently on November 13, 2013, the Company commercially launched IMBRUVICATM in the United States. The Company's competitors include major pharmaceutical and biotechnology companies, clinical reference laboratories and government agencies, as well as academic research institutions that are pursuing research activities similar to the company. The Company has contracted with a third-party logistics company to warehouse IMBRUVICATM and distribute it to wholesalers, distributors, pharmacies, hospitals, and other drug suppliers that ultimately distribute IMBRUVICATM directly to patients. The FDA and applicable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.
» More Articles for PCYC

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: PCYC, DIS, AZO, SCI Mar 17 2015 
AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
own Mar 02 2015 
Weekly 52-Week Highs Highlight: DG, AGN, ADSK, AVGO, PCYC Feb 22 2015 
Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN Mar 03 2014 
comment on PCYC Mar 06 2013 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 26 2011 
Pharmacyclics Inc. Reports Operating Results (10-Q) Feb 08 2011 
Pharmacyclics Inc. Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
Is the Pharmacyclics–AbbVie Merger a Setup? Mar 30 2015
The Risk-to-Reward Ratio of the Pharmacyclics–AbbVie Merger Mar 28 2015
The Pharmacyclics–AbbVie Merger: What Are the Details? Mar 28 2015
The Pharmacyclics–AbbVie Merger: The Basics of Pharmacyclics Mar 25 2015
Could the Pharmacyclics–AbbVie Merger Get Competitive? Mar 24 2015
Is Antitrust a Risk in the Pharmacyclics–AbbVie Merger? Mar 23 2015
Pharmacyclics chief to receive $3.6bn from takeover Mar 23 2015
Rationale for the Pharmacyclics–AbbVie Merger Mar 23 2015
PHARMACYCLICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 23 2015
The Pharmacyclics–AbbVie Merger – Shareholders Could Benefit Mar 20 2015
The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press... Mar 19 2015
New ibrutinib (IMBRUVICA®) Data to be Presented at American Association for Cancer Research (AACR)... Mar 19 2015
PHARMACYCLICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Mar 18 2015
Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Analyst Blog Mar 18 2015
Pharmacyclics' Imbruvica Encourages in a Phase III Study - Analyst Blog Mar 17 2015
AbbVie to Buy Pharmacyclics: Biotech ETFs to Watch - ETF News And Commentary Mar 17 2015
PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 17 2015
Cramer: Skepticism too thick Mar 16 2015
Pharmacyclics cancer drug successful as combination therapy - independent panel Mar 16 2015
Why the Bull Isn't Done Running - Video Blog Mar 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK